fda semaglutide compounding Troubling Findings in Study of GLP-1 Compounders US FDA to reconsider decision

Large-scale clinical trials, including cardiovascular outcome studies, have not identified increased fracture risk as a prominent adverse effect of GLP-1 therapy

No other pharmaceutical intervention had consistently produced double-digit percentage weight loss in a large clinical population

The GWAS was performed including covariates as described in equation 1 above, with the addition of five genetic principal components to account for fine-scale genetic ancestry, and indicator variables to account for variation in the genotyping platform

Pencek R, Blickensderfer A, Li Y, Brunell SC, Anderson PW (2012) Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index